Health Care

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
AstraZeneca's COVID-19 Prevention Therapy Cuts Risk Of Infection In Patients With Weaker Immunity, Data Shows
Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show
Integer Can Drive Consolidation Of Medical Device Outsourcing, Bullish Analyst Projects

Health Care Recent News

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high response rates and sustained clinical benefits in trials.
Elon Musk's Neuralink Patient, Noland Arbaugh, Shares His Journey From Paralysis To Cyborg: 'Once You Get A Taste For Using It…'
Noland Arbaugh, the first Neuralink patient, shared details about his journey from paralysis to functioning better thanks to the implant.
Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc has agreed to pay up to $250 million.
Back Of The Fridge Treasures: 5 Ways To Transform Leftovers And Feel Good About Reducing Food Waste
Leftovers don't have to be a drag. With a little creativity and a fun approach, you can transform them into something exciting and new while doing your bit to cut down on food waste. Now, go open that fridge and get creative!
Boston Scientific's Upside With Cardiology Devices Drives Momentum
Mizuho Securities raises target for Boston Scientific, predicting double-digit growth in cardiology. Surge in Farapulse adoption and Watchman FLX upside driving momentum.
What's Going On With NVIDIA Stock Today?
NVIDIA collaborates on ORBIT-Surgical, a simulation framework for training surgical robots, ahead of its debut at ICRA.
The Oncology Institute, Inc. Reports Q1 Loss, Lags Revenue Estimates
The Oncology Institute, Inc. (NASDAQ: TOI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Novo Nordisk confirms there is no anticipated shortage of Wegovy in Denmark, despite prior warnings from the Danish Medicines Agency about limited supplies. The company addresses high demand and reassures the availability of all doses.
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Ascendis Pharma announces FDA's extension of the review date for TransCon PTH for adults with hypoparathyroidism to August 14, 2024. TransCon PTH aims to address low calcium levels due to hypoparathyroidism.
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease using Lilly branding. Corrective measures include compliance with federal law for tirzepatide products.
Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
Cheating on drug tests among American workers has reached a 30-year high, with Quest Diagnostics Inc. reporting 31,000 tampered samples out of 5.5 million in 2023. The rise in synthetic urine use and additives, along with varying state marijuana laws, poses challenges.
Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1 Results
Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Stock Brokers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers